secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001818382-24-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024
--------------------------------------------------------------------------------

- Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.
- BLA for HAV in vascular trauma accepted with Priority Review; PDUFA date Aug 10, 2024.
- Raised ~$43M net from public offering in March 2024; additional $20M draw from Oberland facility.
- Total operating expenses $26.6M flat QoQ; R&D $21.3M up from $17.3M YoY.
- Preparations for US launch ongoing: hired VP Sales, completed Budget Impact Model, seeking ICD-10 code.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/0001818382-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/huma-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer